Clinical Trial Update: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating recombinant human C1 inhibitor for acute attacks in hereditary angioedema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Recombinant human C1 inhibitor (C1 esterase inhibitor, recombinant)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Genetic Disorders | Phase 2 | Status: COMPLETED